Recent advances in Charcot-Marie-Tooth disease

Area of Science:

• Neurology
• Genetics
• Molecular Biology

Background:

• Charcot-Marie-Tooth disease is the most common inherited peripheral neuropathy and a prevalent hereditary neuromuscular disorder.
• The genetic landscape of Charcot-Marie-Tooth disease encompasses over 70 genes, with ongoing discoveries expanding this spectrum.
• Significant phenotypic variability accompanies the genetic diversity, posing challenges for diagnosis and management.

Purpose of the Study:

• To review recent advancements in Charcot-Marie-Tooth disease.
• To highlight new additions to the genetic spectrum of the disease.
• To discuss novel molecular techniques and update on therapeutic strategies.

Main Methods:

• Review of recent scientific literature on Charcot-Marie-Tooth disease.
• Analysis of newly identified disease-causing genes.
• Evaluation of outcomes from completed and ongoing clinical trials.
• Assessment of preclinical data for emerging therapeutic compounds.

Main Results:

• Identification of several new Charcot-Marie-Tooth disease-associated genes (e.g., SBF1, DHTKD1, TFG).
• Next-generation sequencing technologies have accelerated gene discovery and altered genetic screening.
• Large-scale trials of ascorbic acid for Charcot-Marie-Tooth 1A yielded negative results.
• Promising preclinical findings observed with lonaprisan, curcumin, and HDAC6 inhibitors in animal models.

Conclusions:

• Charcot-Marie-Tooth disease genetics and phenotypes are increasingly complex due to rapid gene discovery.
• High-throughput molecular technologies have revolutionized genetic identification in Charcot-Marie-Tooth disease.
• Currently, no definitive therapy exists for Charcot-Marie-Tooth disease, necessitating continued research into novel therapeutic agents.